Cosaic Raises $6M to Scale Its Multifunctional Yeast Ingredient Across Global Food Markets
- Julie Kriegshaber
- May 6
- 3 min read
Too long to read? Go for the highlights below.
A single yeast-derived ingredient could replace multiple food additives, offering cleaner labels and simpler formulations for mainstream food and drink products.
Swiss startup Cosaic has raised $6M in a seed extension round, backed by DSM-Firmenich Ventures, bringing its total funding to $12.5M.
With regulatory approvals underway in the US and Europe, Cosaic is positioning its flagship ingredient, Cosaic Neo, for commercial launch.
Food manufacturers face a persistent tension: consumers want simpler ingredient lists, but formulating products without the usual battery of emulsifiers, stabilisers, and thickeners is technically demanding. A Swiss startup believes a single yeast-derived ingredient can resolve that tension, and investors are beginning to agree.
From Brewery Flasks to Food Shelves
Cosaic, formerly known as Cultivated Biosciences, is a Swiss biotechnology company that uses yeast fermentation to produce multifunctional food ingredients. Its process centres on a non-GMO oleaginous yeast, a microorganism that naturally accumulates large quantities of lipids, or fats, within its cells. The yeast is grown in a controlled bioreactor, fed on sugars, nitrogen sources, and mineral and vitamin supplements. Once cultivated, the biomass undergoes a non-chemical extraction process using standard industrial equipment, which breaks open the cells and isolates a stable emulsion with a distinctive off-white appearance.
The resulting ingredient, Cosaic Neo, is a compositionally complex material. It contains between 8 and 15 per cent protein, 45 to 60 per cent fat, of which 13 to 22 per cent is saturated, and 25 to 45 per cent fibre. This combination of macronutrients means it can simultaneously provide bulk, nutritional value, creaminess, and emulsification stability, functions that would ordinarily require several separate ingredients. Cosaic claims it delivers eight distinct functional benefits within a single formulation component.
The practical applications span a wide range of product categories, including ready-to-drink protein shakes, coffee creamers, non-dairy milks, mayonnaise, sauces, and creamy liqueurs. In each case, it is designed to substitute for animal-derived ingredients such as whey or eggs, as well as industrial additives like lecithin, a common emulsifier extracted from soya or sunflower.
Investor Confidence in a Difficult Climate
Cosaic recently closed a $6M extension of its seed round, led by DSM-Firmenich Ventures, the venture capital arm of the Dutch-Swiss chemicals and ingredients group DSM-Firmenich. Additional participants included a large Swiss family office, deep tech investor Kickfund, and existing backers Navus Ventures and Zuercher Kantonalbank. The raise brings Cosaic's cumulative funding to $12.5M.
The timing is notable. Fermentation-focused food technology companies experienced a 43.5 per cent decline in financing in 2024, making fresh capital particularly hard to secure. That Cosaic attracted a lead investor of DSM-Firmenich's scale suggests the market sees genuine commercial potential in its approach, particularly given the company's capital-efficient model, which relies on contract manufacturing rather than building proprietary production facilities.
This round follows a strategic partnership announced in November 2024 with Ingredion, a major global ingredient supplier, which will assist Cosaic with its commercialisation strategy and co-develop new products alongside it. Together, these moves suggest a deliberate effort to reach market through established distribution channels rather than independently. The broader fermentation sector has seen a modest recovery in 2025, with several companies securing meaningful rounds despite the difficult fundraising backdrop.
Regulatory Progress and the Road to Market
The $6M will be allocated across three areas: advancing regulatory approvals in the United States and Europe, scaling production with a contract manufacturer, and running industrial trials with large food and beverage clients.
Cosaic is prioritising the US as its first commercial market, citing a more streamlined regulatory pathway. The company's yeast strain carries what is known as a qualified presumption of safety, a designation that indicates a substantial existing body of evidence about its safety profile. This does not eliminate the need for regulatory approval, but it provides a meaningful head start in building the dossier that authorities require.
The clean-label imperative driving Cosaic's strategy is well supported by consumer data. Research cited by the company indicates that 76 per cent of consumers are willing to pay a premium for clean-label products, and 74 per cent of EU citizens consider simple ingredient lists an important factor in purchasing decisions. As pressure mounts on food companies to reduce additives and reformulate products, ingredients that consolidate multiple functions into one component have clear commercial appeal. The parallel growth of fermentation-derived ingredients that convert waste streams into functional food components reflects a broader industry shift towards efficiency and ingredient simplification.
Whether Cosaic Neo can win shelf space in a competitive ingredients market will ultimately depend on price parity and the results of those industrial trials. For now, the combination of a strategic partnership, a lead investor with deep industry connections, and a product targeting a genuine formulation problem gives Cosaic a credible platform from which to pursue commercialisation.
